ヘルステック

FerroptoCure Inc Concludes Series A Round

Tokyo biotech startup FerroptoCure has raised ¥460 million in Series A funding. This money will help speed up developing therapies that use ferroptosis. Ferroptosis is a type of cell death caused by oxidative stress. Investors are: ANRI Tokyo University of Science Innovation Capital Diamond Medino Capital Vision Incubate Japan Science and Technology Agency Total funding from this round is expected to hit ¥960 million, thanks to extra subsidies from AMED’s Drug Discovery Venture Ecosystem Strengthening Project. Also Read: FUJIFILM and argenx Extend Collaboration to U.S. Operations The company will use the funds for key purposes: Advancing overseas clinical trials for its lead candidate, FC-004. Developing other pipelines. Expanding its capabilities for future growth. AMED's support shows Japan's effort to boost its drug discovery ecosystem. They are backing ventures that focus…